Literature DB >> 17584424

An evaluation of an insulin transfer programme delivered in a group setting.

Kate Kelley1, Carole Dempsey.   

Abstract

AIM: This study assesses the efficacy of a group education programme through the improvement of the patients' HbA1c status and their overall understanding of diabetes.
BACKGROUND: The transfer from tablets to insulin is a crucial time for patients with diabetes. The provision of diabetes education is essential, enabling patients to develop a knowledge base from which to manage their diabetes and consequently take control of their life. The growing numbers of referrals for insulin transfer meant that the traditional one-to-one education approach is unrealistic and a local diabetes team developed a group programme to meet the demand.
METHOD: The study has a pre-post test design. Biomedical outcomes are: HbA1c and weight. Self-report outcomes are: diabetes knowledge, diabetes treatment satisfaction (DTSQ) and quality of life (EQ-5D). All outcomes were measured prior to the group education programme and then after the programme had been completed. HbA1c was also measured again at three months after the education programme had finished. A repeated measures anova was used to analyse the main data.
RESULTS: Seventy-two patients were recruited into the study and at follow-up 77% (n = 65) remained in the study. The mean age of the participants was 64.5 (SD 12.01) years and the median time since being diagnosed with diabetes was 7.3 years (range two months to 20 years). There was an overall significant reduction in the HbA1c scores across the three time points (F(1.5) = 57.87, p < 0.0001). Post hoc tests indicate there are significant reductions (p < 0.0001) from the pregroup mean at both the postgroup (9.84% vs. 8.54%) and three-month follow up means (9.84% vs. 8.10%). The difference from times 2 and 3 (8.54% vs. 8.10%) was also significant (p < 0.0001). There were no significant changes in weight. After the programme, satisfaction with diabetes treatment was high and knowledge about diabetes had improved (t(54) = 7.46, p < 0.0001). There were significant improvements reported on the five health dimensions of the EQ-5D.
CONCLUSION: These results indicate that a group education programme can be an effective method of helping patients transfer from tablets to insulin. RELEVANCE TO CLINICAL PRACTICE: These group sessions have reduced waiting times for patients transferring from tablets to insulin and have proved an effective use of time management by Diabetes Specialist Nurses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584424     DOI: 10.1111/j.1365-2702.2007.01772.x

Source DB:  PubMed          Journal:  J Clin Nurs        ISSN: 0962-1067            Impact factor:   3.036


  6 in total

1.  Bolus guide: a novel insulin bolus dosing decision support tool based on selection of carbohydrate ranges.

Authors:  Gali Shapira; Ofer Yodfat; Arava HaCohen; Paul Feigin; Richard Rubin
Journal:  J Diabetes Sci Technol       Date:  2010-07-01

2.  How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference.

Authors:  Mark Peyrot; Richard R Rubin
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 17.152

3.  Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ).

Authors:  Richard R Rubin; Mark Peyrot
Journal:  Health Qual Life Outcomes       Date:  2010-03-24       Impact factor: 3.186

4.  Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study.

Authors:  Shoko Tsukube; Yukio Ikeda; Takashi Kadowaki; Masato Odawara
Journal:  Diabetes Ther       Date:  2015-06-04       Impact factor: 2.945

5.  Development and validation of the Diabetes Medication System Rating Questionnaire-Short Form.

Authors:  M Peyrot; Y Xu; R R Rubin
Journal:  Diabet Med       Date:  2014-04-18       Impact factor: 4.359

6.  Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.

Authors:  J H Best; K S Boye; R R Rubin; D Cao; T H Kim; M Peyrot
Journal:  Diabet Med       Date:  2009-07       Impact factor: 4.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.